This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Polsky, D. Articles by Osman, I. Search for Related Content PubMed PubMed Citation Articles by Polsky, D. Articles by Osman, I.

HDM2 Protein Overexpression, but not Gene Amplification, is Related to Tumorigenesis of Cutaneous Melanoma¹

Ronald O. Perelman Department of Dermatology [D. P., C. H., K. M., I. O.], Kaplan Comprehensive Cancer Center [I. O.], New York University School of Medicine/Veterans Affairs Medical Center, New York, New York 10016; Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [J. P., A. H., K. B., C. C-C.]; and Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94115 [B. C. B.]

We investigated the role of alterations of HDM2, the human homologue of murine mdm2, in the tumorigenesis and progression of cutaneous melanoma. A well-characterized cohort of 172 cases representing different points in the spectrum of melanocyte transformation (16 dysplastic nevi, 11 melanomas in situ, 107 invasive primaries, and 38 metastatic lesions), as well as 11 human melanoma cell lines were examined by immunohistochemistry and Western blotting for HDM2 protein expression, and by either Southern blotting (SB) or fluorescence in situ hybridization for HDM2 gene amplification. HDM2 overexpression, defined as >20% tumor cells showing nuclear immunoreactivity, was observed in 1 of 16 (6%) dysplastic nevi, 3 of 11 (27%) melanomas in situ, and 81 of 145 (56%) invasive primary and metastatic melanomas. Comparable frequencies of HDM2 overexpression were observed among invasive primary cases with differing tumor thicknesses as well as among the metastatic cases: 21 of 40 (53%) at 1.5 mm; 31 of 50 (62%) at 1.6–3.9 mm; 10 of 17 (58%) at >4 mm; and 19 of 38 (50%) metastases. HDM2 amplification was observed in 1 of 88 (1%) primary cases using fluorescence in situ hybridization, and in 0 of 12 (0%) metastatic cases that overexpressed HDM2 using SB. Melanoma cell lines expressed HDM2 protein, but there was no evidence of amplification by SB. Our data suggest that HDM2 protein overexpression is common in invasive and metastatic melanoma. Observing HDM2 overexpression in noninvasive melanoma suggests that expression of this oncogene may play an early role in melanocyte transformation. HDM2 amplification occurs infrequently, and other mechanisms that up-regulate HDM2 expression are under investigation.

This article has been cited by other articles:

				A. Forslund, Z. Zeng, L.-X. Qin, S. Rosenberg, M. Ndubuisi, H. Pincas, W. Gerald, D. A. Notterman, F. Barany, and P. B. Paty MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers Mol. Cancer Res., February 1, 2008; 6(2): 205 - 211. [Abstract] [Full Text] [PDF]

				M. Yang, Y. Guo, X. Zhang, X. Miao, W. Tan, T. Sun, D. Zhao, D. Yu, J. Liu, and D. Lin Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer Carcinogenesis, September 1, 2007; 28(9): 1996 - 2001. [Abstract] [Full Text] [PDF]

				H. C.A. Graat, J. E. Carette, F. H.E. Schagen, L. T. Vassilev, W. R. Gerritsen, G. J.L. Kaspers, P. I.J.M. Wuisman, and V. W. van Beusechem Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53 Mol. Cancer Ther., May 1, 2007; 6(5): 1552 - 1561. [Abstract] [Full Text] [PDF]

				L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani Toward a Molecular Classification of Melanoma J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620. [Abstract] [Full Text] [PDF]

				K. S.M. Smalley, R. Contractor, N. K. Haass, A. N. Kulp, G. E. Atilla-Gokcumen, D. S. Williams, H. Bregman, K. T. Flaherty, M. S. Soengas, E. Meggers, et al. An Organometallic Protein Kinase Inhibitor Pharmacologically Activates p53 and Induces Apoptosis in Human Melanoma Cells Cancer Res., January 1, 2007; 67(1): 209 - 217. [Abstract] [Full Text] [PDF]

				E. Lopez-Knowles, S. Hernandez, M. Kogevinas, J. Lloreta, A. Amoros, A. Tardon, A. Carrato, S. Kishore, C. Serra, N. Malats, et al. The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors. Clin. Cancer Res., October 15, 2006; 12(20): 6029 - 6036. [Abstract] [Full Text] [PDF]

				K. Onel and C. Cordon-Cardo MDM2 and Prognosis Mol. Cancer Res., January 1, 2004; 2(1): 1 - 8. [Abstract] [Full Text] [PDF]

				S. R. Alonso, P. Ortiz, M. Pollan, B. Perez-Gomez, L. Sanchez, M. J. Acuna, R. Pajares, F. J. Martinez-Tello, C. M. Hortelano, M. A. Piris, et al. Progression in Cutaneous Malignant Melanoma Is Associated with Distinct Expression Profiles: A Tissue Microarray-Based Study Am. J. Pathol., January 1, 2004; 164(1): 193 - 203. [Abstract] [Full Text] [PDF]

				D. Polsky, K. Melzer, C. Hazan, K. S. Panageas, K. Busam, M. Drobnjak, H. Kamino, J. G. Spira, A. W. Kopf, A. Houghton, et al. HDM2 Protein Overexpression and Prognosis in Primary Malignant Melanoma J Natl Cancer Inst, December 4, 2002; 94(23): 1803 - 1806. [Abstract] [Full Text] [PDF]

				W. C. Hahn and R. A. Weinberg Rules for Making Human Tumor Cells N. Engl. J. Med., November 14, 2002; 347(20): 1593 - 1603. [Full Text] [PDF]